Starpharma today announced that it has been invited once more to present at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 7-8 October.

The PODD conference showcases the latest advances in drug delivery and provides networking opportunities with senior scientific and commercial executives from many of the major international pharmaceutical companies. This year’s PODD conference will be chaired by AstraZeneca’s Head of Drug Delivery, Dr Shawn Davis.

Presenters and attendees of the PODD conference include senior licensing and product development executives from pharma and biotech companies, including GSK, Pfizer, Takeda, Roche Genentech, Merck, AstraZeneca, Eli Lily, BMS, Novartis, Eisai, Boehringer Ingelheim, AMGEN and Bristol-Myers Squibb.

This year, Starpharma will be represented by its VP of Research, Dr David Owen. Dr Owen will be presenting an overview of the benefits of the DEP^® platform, including:

• Recent DEP^® results demonstrating its benefit, including when used in combination with other oncology agents (e.g. Lynparza^®, Erbitux^®)
• Commercial and performance benefits of the DEP^® technology in partnered programs, including AZD0466, which was recently authorised by the FDA to proceed under IND to human clinical trials
• Broad applicability of DEP^® in new technology areas, including radiopharmaceuticals and antibody-drug conjugates (ADCs)
• Snapshot of Starpharma’s internal DEP^® program, focussing on three clinical-stage products: DEP^® docetaxel, DEP^® cabazitaxel and DEP^® irinotecan

A copy of the presentation will be made available on Starpharma’s website at www.starpharma.com.

Starpharma will also be conducting partnering discussions with pharmaceutical companies at the conference.

The slide presentation is available here (pdf file, 1,997kb)

Download ASX Announcement: Starpharma to present at US Drug Delivery Conference (pdf file, 58kb)